TABLE 2.
Diagnostic performance of mNGS and CMT in analysis of 1,473 samples
| Sample type | Positive % agreement (95% CI)a |
Negative % agreement (95% CI)a |
||||
|---|---|---|---|---|---|---|
| mNGS | CMT | P | mNGS | CMT | P | |
| Blood | 44.9 (39.8–50.1) | 23.0 (18.7–27.4) | <0.001 | 92.3 (89.0–95.5) | 95.8 (93.3–98.2) | 0.095 |
| CSF | 44.5 (37.1–51.9) | 7.5 (3.6–11.4) | <0.001 | 94.0 (91.7–96.4) | 98.5 (97.3–99.7) | 0.001 |
| BALF | 67.6 (60.9–74.2) | 41.5 (29.8–44.9) | <0.001 | 87.5 (64.6–110.4) | 87.5 (64.6–110.4) | >0.99 |
| Sputum | 74.1 (64.5–83.6) | 40.7 (30.0–51.4) | <0.001 | 80.0 (44.9–115.1) | 100 | >0.99 |
| Total | 53.1 (49.7–56.6) | 25.8 (22.8–28.9) | <0.001 | 93.2 (91.3–95.1) | 97.2 (95.9–98.2) | 0.001 |
a
Positive and negative percent agreements of mNGS and CMT were compared to the final clinical diagnosis. BALF, bronchoalveolar lavage fluid; CMT, conventional microbiological tests; CSF, cerebrospinal fluid; mNGS, metagenomic next-generation sequencing.